| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 41 | 2022 | 957 | 6.120 |
Why?
|
| Mammography | 26 | 2022 | 169 | 4.610 |
Why?
|
| Magnetic Resonance Imaging | 17 | 2022 | 107 | 4.410 |
Why?
|
| Early Detection of Cancer | 26 | 2022 | 513 | 4.160 |
Why?
|
| Textile Industry | 20 | 2015 | 20 | 2.540 |
Why?
|
| Breast | 13 | 2022 | 85 | 2.460 |
Why?
|
| Occupational Exposure | 22 | 2015 | 67 | 2.330 |
Why?
|
| Breast Density | 8 | 2022 | 31 | 1.760 |
Why?
|
| Female | 83 | 2022 | 12780 | 1.700 |
Why?
|
| Humans | 93 | 2023 | 17822 | 1.590 |
Why?
|
| Middle Aged | 58 | 2022 | 8020 | 1.450 |
Why?
|
| Mass Screening | 13 | 2022 | 678 | 1.400 |
Why?
|
| Lung Neoplasms | 6 | 2021 | 260 | 1.340 |
Why?
|
| Neoplasms, Second Primary | 2 | 2020 | 29 | 1.310 |
Why?
|
| Ovarian Neoplasms | 4 | 2013 | 50 | 1.280 |
Why?
|
| Aged | 51 | 2022 | 6173 | 1.250 |
Why?
|
| Occupational Diseases | 14 | 2015 | 41 | 1.190 |
Why?
|
| Risk Factors | 30 | 2021 | 3362 | 1.040 |
Why?
|
| Colonoscopy | 5 | 2015 | 253 | 0.940 |
Why?
|
| Adult | 39 | 2023 | 7708 | 0.920 |
Why?
|
| Parity | 3 | 2009 | 74 | 0.880 |
Why?
|
| Colorectal Neoplasms | 8 | 2014 | 615 | 0.860 |
Why?
|
| Neoplasms | 8 | 2021 | 445 | 0.850 |
Why?
|
| Population Surveillance | 6 | 2022 | 264 | 0.810 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 4 | 2011 | 65 | 0.800 |
Why?
|
| China | 26 | 2015 | 132 | 0.780 |
Why?
|
| Cancer Survivors | 2 | 2022 | 85 | 0.780 |
Why?
|
| United States | 23 | 2023 | 4007 | 0.720 |
Why?
|
| BRCA1 Protein | 1 | 2020 | 6 | 0.720 |
Why?
|
| Dust | 11 | 2015 | 22 | 0.660 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2020 | 382 | 0.630 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2022 | 247 | 0.620 |
Why?
|
| Advisory Committees | 2 | 2017 | 113 | 0.620 |
Why?
|
| Antidepressive Agents | 2 | 2010 | 156 | 0.610 |
Why?
|
| Patient Outcome Assessment | 1 | 2018 | 28 | 0.580 |
Why?
|
| Cohort Studies | 18 | 2021 | 2590 | 0.580 |
Why?
|
| Endometrial Neoplasms | 2 | 2008 | 35 | 0.570 |
Why?
|
| Patient Participation | 2 | 2018 | 134 | 0.570 |
Why?
|
| Scoliosis | 1 | 2017 | 3 | 0.560 |
Why?
|
| Registries | 11 | 2020 | 472 | 0.540 |
Why?
|
| Risk Assessment | 14 | 2015 | 1103 | 0.530 |
Why?
|
| Postoperative Complications | 1 | 2017 | 102 | 0.520 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2016 | 24 | 0.520 |
Why?
|
| Time Factors | 13 | 2017 | 1097 | 0.520 |
Why?
|
| Melanoma | 1 | 2016 | 35 | 0.520 |
Why?
|
| Anesthesia | 1 | 2015 | 4 | 0.520 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 55 | 0.510 |
Why?
|
| Skin Neoplasms | 1 | 2016 | 57 | 0.500 |
Why?
|
| Aged, 80 and over | 13 | 2019 | 1931 | 0.490 |
Why?
|
| Incidence | 13 | 2015 | 1269 | 0.490 |
Why?
|
| Age Factors | 9 | 2017 | 923 | 0.480 |
Why?
|
| Mastectomy | 6 | 2022 | 36 | 0.480 |
Why?
|
| Colonic Neoplasms | 3 | 2013 | 158 | 0.450 |
Why?
|
| Healthcare Disparities | 4 | 2018 | 204 | 0.450 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2013 | 4 | 0.450 |
Why?
|
| Male | 14 | 2018 | 10145 | 0.440 |
Why?
|
| Young Adult | 8 | 2021 | 2464 | 0.430 |
Why?
|
| Colonic Polyps | 2 | 2011 | 35 | 0.430 |
Why?
|
| Deep Sedation | 1 | 2013 | 3 | 0.430 |
Why?
|
| Pelvic Neoplasms | 1 | 2013 | 1 | 0.430 |
Why?
|
| Abdominal Neoplasms | 1 | 2013 | 2 | 0.430 |
Why?
|
| Colonography, Computed Tomographic | 1 | 2013 | 10 | 0.420 |
Why?
|
| Odds Ratio | 8 | 2015 | 673 | 0.420 |
Why?
|
| Case-Control Studies | 10 | 2023 | 1120 | 0.410 |
Why?
|
| Logistic Models | 9 | 2017 | 928 | 0.390 |
Why?
|
| Rectal Neoplasms | 2 | 2009 | 65 | 0.380 |
Why?
|
| Contraceptives, Oral | 2 | 2008 | 26 | 0.380 |
Why?
|
| Survivors | 2 | 2022 | 150 | 0.370 |
Why?
|
| Decision Making | 4 | 2022 | 184 | 0.370 |
Why?
|
| Stomach Neoplasms | 2 | 2015 | 41 | 0.360 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2014 | 391 | 0.360 |
Why?
|
| Health Care Costs | 1 | 2013 | 229 | 0.360 |
Why?
|
| Esophageal Neoplasms | 2 | 2015 | 115 | 0.350 |
Why?
|
| Medicare | 6 | 2018 | 205 | 0.350 |
Why?
|
| Body Size | 1 | 2010 | 31 | 0.340 |
Why?
|
| Polymorphism, Genetic | 1 | 2010 | 63 | 0.340 |
Why?
|
| Endotoxins | 9 | 2010 | 9 | 0.340 |
Why?
|
| Proportional Hazards Models | 11 | 2015 | 711 | 0.340 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2021 | 211 | 0.340 |
Why?
|
| Gravidity | 1 | 2009 | 8 | 0.330 |
Why?
|
| Influenza Vaccines | 2 | 2023 | 273 | 0.330 |
Why?
|
| Influenza, Human | 2 | 2023 | 265 | 0.320 |
Why?
|
| Adenoma | 1 | 2010 | 94 | 0.320 |
Why?
|
| Preoperative Care | 3 | 2018 | 19 | 0.320 |
Why?
|
| Washington | 4 | 2021 | 383 | 0.310 |
Why?
|
| Silk | 1 | 2008 | 1 | 0.310 |
Why?
|
| Sensitivity and Specificity | 3 | 2019 | 305 | 0.310 |
Why?
|
| Practice Guidelines as Topic | 4 | 2020 | 321 | 0.300 |
Why?
|
| Hormone Replacement Therapy | 1 | 2008 | 22 | 0.300 |
Why?
|
| Pandemics | 4 | 2023 | 287 | 0.280 |
Why?
|
| Multivariate Analysis | 4 | 2017 | 569 | 0.280 |
Why?
|
| Evidence-Based Medicine | 3 | 2017 | 186 | 0.270 |
Why?
|
| Patient Education as Topic | 2 | 2020 | 213 | 0.270 |
Why?
|
| Air Pollutants, Occupational | 4 | 2008 | 16 | 0.270 |
Why?
|
| Menarche | 1 | 2006 | 28 | 0.260 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 2 | 2023 | 52 | 0.260 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 2 | 2023 | 15 | 0.250 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2020 | 376 | 0.250 |
Why?
|
| Wisconsin | 3 | 2010 | 11 | 0.250 |
Why?
|
| Biopsy | 4 | 2021 | 75 | 0.250 |
Why?
|
| Prospective Studies | 7 | 2017 | 1286 | 0.240 |
Why?
|
| Patient Selection | 2 | 2017 | 190 | 0.240 |
Why?
|
| Cardiovascular Diseases | 1 | 2010 | 599 | 0.240 |
Why?
|
| Adolescent | 7 | 2022 | 3690 | 0.230 |
Why?
|
| Postmenopause | 3 | 2022 | 243 | 0.230 |
Why?
|
| Risk | 3 | 2017 | 518 | 0.230 |
Why?
|
| Textiles | 3 | 2010 | 3 | 0.230 |
Why?
|
| Guideline Adherence | 2 | 2016 | 158 | 0.220 |
Why?
|
| Cross-Sectional Studies | 4 | 2022 | 1335 | 0.220 |
Why?
|
| Socioeconomic Factors | 4 | 2017 | 630 | 0.200 |
Why?
|
| Emotions | 1 | 2022 | 34 | 0.200 |
Why?
|
| Influenza A virus | 1 | 2022 | 13 | 0.200 |
Why?
|
| Surveys and Questionnaires | 5 | 2014 | 1323 | 0.190 |
Why?
|
| Retrospective Studies | 4 | 2017 | 2467 | 0.190 |
Why?
|
| Age Distribution | 2 | 2020 | 246 | 0.190 |
Why?
|
| Medical Informatics | 1 | 2021 | 38 | 0.180 |
Why?
|
| Health Care Rationing | 1 | 2021 | 12 | 0.180 |
Why?
|
| Triage | 1 | 2021 | 16 | 0.180 |
Why?
|
| Physical Examination | 2 | 2021 | 20 | 0.180 |
Why?
|
| Genome-Wide Association Study | 1 | 2022 | 249 | 0.180 |
Why?
|
| Pregnancy | 5 | 2010 | 1529 | 0.180 |
Why?
|
| Reproducibility of Results | 2 | 2019 | 381 | 0.180 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2012 | 379 | 0.170 |
Why?
|
| Pamphlets | 1 | 2020 | 7 | 0.170 |
Why?
|
| Mutation | 1 | 2020 | 131 | 0.170 |
Why?
|
| Awareness | 1 | 2020 | 17 | 0.170 |
Why?
|
| Perception | 1 | 2019 | 58 | 0.160 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 720 | 0.160 |
Why?
|
| False Positive Reactions | 3 | 2013 | 26 | 0.160 |
Why?
|
| Abortion, Spontaneous | 2 | 2010 | 47 | 0.160 |
Why?
|
| Anticarcinogenic Agents | 2 | 2010 | 13 | 0.160 |
Why?
|
| Communication | 1 | 2020 | 194 | 0.150 |
Why?
|
| Health Services Accessibility | 2 | 2018 | 292 | 0.150 |
Why?
|
| Obesity | 2 | 2017 | 842 | 0.150 |
Why?
|
| Research Support as Topic | 1 | 2018 | 20 | 0.150 |
Why?
|
| Smoking | 5 | 2017 | 484 | 0.150 |
Why?
|
| Trust | 1 | 2018 | 31 | 0.150 |
Why?
|
| Quality Improvement | 2 | 2017 | 194 | 0.150 |
Why?
|
| Language | 1 | 2018 | 53 | 0.140 |
Why?
|
| Databases, Factual | 2 | 2016 | 315 | 0.140 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2018 | 53 | 0.140 |
Why?
|
| Spine | 1 | 2017 | 7 | 0.140 |
Why?
|
| Spinal Fusion | 1 | 2017 | 5 | 0.140 |
Why?
|
| Gonadal Steroid Hormones | 2 | 2022 | 27 | 0.140 |
Why?
|
| Telephone | 2 | 2017 | 161 | 0.140 |
Why?
|
| Clinical Protocols | 1 | 2017 | 43 | 0.140 |
Why?
|
| Health Personnel | 1 | 2018 | 126 | 0.140 |
Why?
|
| Cotton Fiber | 4 | 2010 | 4 | 0.140 |
Why?
|
| Medical Oncology | 2 | 2014 | 32 | 0.130 |
Why?
|
| Dermatology | 1 | 2016 | 6 | 0.130 |
Why?
|
| Tumor Burden | 1 | 2016 | 19 | 0.130 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 59 | 0.130 |
Why?
|
| Safety-net Providers | 1 | 2017 | 52 | 0.130 |
Why?
|
| Decision Support Techniques | 1 | 2017 | 88 | 0.130 |
Why?
|
| International Cooperation | 2 | 2013 | 17 | 0.130 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 417 | 0.130 |
Why?
|
| Cost-Benefit Analysis | 2 | 2016 | 250 | 0.130 |
Why?
|
| Ethnic Groups | 2 | 2017 | 485 | 0.130 |
Why?
|
| SEER Program | 4 | 2018 | 91 | 0.130 |
Why?
|
| Primary Health Care | 3 | 2016 | 770 | 0.120 |
Why?
|
| Social Class | 1 | 2015 | 121 | 0.120 |
Why?
|
| Comorbidity | 2 | 2017 | 597 | 0.120 |
Why?
|
| Work Schedule Tolerance | 1 | 2014 | 7 | 0.120 |
Why?
|
| Preventive Health Services | 1 | 2016 | 160 | 0.120 |
Why?
|
| Patient Compliance | 1 | 2016 | 301 | 0.110 |
Why?
|
| Hyperplasia | 2 | 2011 | 6 | 0.110 |
Why?
|
| Magnetic Fields | 1 | 2013 | 6 | 0.110 |
Why?
|
| Reminder Systems | 1 | 2014 | 80 | 0.110 |
Why?
|
| Promoter Regions, Genetic | 1 | 2012 | 15 | 0.100 |
Why?
|
| Estrogen Receptor beta | 1 | 2012 | 10 | 0.100 |
Why?
|
| Influenza B virus | 2 | 2023 | 9 | 0.100 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2013 | 99 | 0.100 |
Why?
|
| Biomedical Research | 1 | 2013 | 86 | 0.100 |
Why?
|
| Radiology | 3 | 2021 | 8 | 0.100 |
Why?
|
| Body Mass Index | 3 | 2017 | 967 | 0.100 |
Why?
|
| Survival Rate | 1 | 2013 | 260 | 0.100 |
Why?
|
| Seasons | 2 | 2023 | 105 | 0.100 |
Why?
|
| Diagnostic Imaging | 1 | 2012 | 45 | 0.100 |
Why?
|
| Silicon Dioxide | 2 | 2010 | 3 | 0.100 |
Why?
|
| Self Report | 1 | 2013 | 253 | 0.100 |
Why?
|
| Outcome Assessment (Health Care) | 1 | 2012 | 228 | 0.090 |
Why?
|
| Child | 3 | 2023 | 2497 | 0.090 |
Why?
|
| Prognosis | 1 | 2013 | 609 | 0.090 |
Why?
|
| Epoxide Hydrolases | 1 | 2011 | 2 | 0.090 |
Why?
|
| Neoplasm Staging | 3 | 2018 | 330 | 0.090 |
Why?
|
| Meat | 1 | 2011 | 27 | 0.090 |
Why?
|
| Follow-Up Studies | 2 | 2011 | 1219 | 0.090 |
Why?
|
| Quality Indicators, Health Care | 1 | 2012 | 182 | 0.090 |
Why?
|
| Reproductive History | 2 | 2013 | 17 | 0.090 |
Why?
|
| Human Growth Hormone | 1 | 2010 | 5 | 0.090 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2010 | 14 | 0.090 |
Why?
|
| Colon | 1 | 2010 | 20 | 0.090 |
Why?
|
| Physical Exertion | 1 | 2010 | 22 | 0.090 |
Why?
|
| Patient-Centered Care | 1 | 2012 | 197 | 0.090 |
Why?
|
| Cause of Death | 1 | 2010 | 181 | 0.080 |
Why?
|
| Insurance, Health | 1 | 2011 | 183 | 0.080 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 100 | 0.080 |
Why?
|
| Infant | 2 | 2023 | 1198 | 0.080 |
Why?
|
| Regression Analysis | 1 | 2009 | 300 | 0.080 |
Why?
|
| Ovulation | 1 | 2008 | 5 | 0.080 |
Why?
|
| Motor Activity | 1 | 2010 | 212 | 0.080 |
Why?
|
| Residence Characteristics | 3 | 2017 | 251 | 0.080 |
Why?
|
| Gram-Negative Bacteria | 1 | 2008 | 4 | 0.080 |
Why?
|
| Child, Preschool | 2 | 2023 | 1424 | 0.070 |
Why?
|
| Inflammation | 1 | 2008 | 64 | 0.070 |
Why?
|
| Massachusetts | 1 | 2008 | 94 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2008 | 129 | 0.070 |
Why?
|
| Vaccination | 2 | 2023 | 655 | 0.070 |
Why?
|
| Epidemiological Monitoring | 4 | 2010 | 25 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2008 | 216 | 0.070 |
Why?
|
| Inhalation Exposure | 1 | 2007 | 5 | 0.070 |
Why?
|
| Environmental Monitoring | 4 | 2010 | 26 | 0.070 |
Why?
|
| Contraceptive Agents, Female | 1 | 2007 | 12 | 0.070 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2009 | 172 | 0.070 |
Why?
|
| Treatment Outcome | 1 | 2010 | 1265 | 0.070 |
Why?
|
| Abortion, Induced | 1 | 2006 | 18 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2020 | 219 | 0.070 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2006 | 15 | 0.070 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 354 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2008 | 329 | 0.070 |
Why?
|
| Brain Neoplasms | 1 | 2006 | 15 | 0.070 |
Why?
|
| Menopause | 1 | 2006 | 69 | 0.070 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2006 | 1 | 0.060 |
Why?
|
| Thyroid Neoplasms | 1 | 2005 | 12 | 0.060 |
Why?
|
| Patient Satisfaction | 2 | 2020 | 212 | 0.060 |
Why?
|
| Liver Neoplasms | 1 | 2005 | 40 | 0.060 |
Why?
|
| Pancreatic Neoplasms | 1 | 2006 | 67 | 0.060 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2011 | 537 | 0.060 |
Why?
|
| Hispanic Americans | 2 | 2017 | 404 | 0.060 |
Why?
|
| European Continental Ancestry Group | 2 | 2017 | 529 | 0.060 |
Why?
|
| Workplace | 1 | 2003 | 30 | 0.060 |
Why?
|
| Epidemiologic Methods | 3 | 2010 | 81 | 0.050 |
Why?
|
| African Americans | 2 | 2017 | 472 | 0.050 |
Why?
|
| Research | 1 | 2003 | 65 | 0.050 |
Why?
|
| Presenteeism | 1 | 2023 | 2 | 0.050 |
Why?
|
| Vaccines, Inactivated | 1 | 2023 | 67 | 0.050 |
Why?
|
| Receptors, Estrogen | 1 | 2022 | 51 | 0.050 |
Why?
|
| Tamoxifen | 1 | 2022 | 56 | 0.050 |
Why?
|
| Likelihood Functions | 2 | 2014 | 45 | 0.050 |
Why?
|
| Testosterone | 1 | 2022 | 23 | 0.050 |
Why?
|
| Estradiol | 1 | 2022 | 24 | 0.050 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2022 | 23 | 0.050 |
Why?
|
| Medical History Taking | 1 | 2021 | 35 | 0.050 |
Why?
|
| Focus Groups | 1 | 2021 | 147 | 0.050 |
Why?
|
| Reference Standards | 1 | 2020 | 15 | 0.040 |
Why?
|
| Boston | 1 | 2020 | 35 | 0.040 |
Why?
|
| Confidence Intervals | 2 | 2010 | 237 | 0.040 |
Why?
|
| Health Facilities | 1 | 2018 | 17 | 0.040 |
Why?
|
| Mastectomy, Segmental | 1 | 2017 | 20 | 0.040 |
Why?
|
| Chemoprevention | 1 | 2017 | 12 | 0.040 |
Why?
|
| Social Stigma | 1 | 2017 | 19 | 0.030 |
Why?
|
| Benchmarking | 1 | 2017 | 46 | 0.030 |
Why?
|
| Self Efficacy | 1 | 2017 | 68 | 0.030 |
Why?
|
| Research Design | 2 | 2010 | 376 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2017 | 305 | 0.030 |
Why?
|
| Insurance Claim Review | 1 | 2016 | 61 | 0.030 |
Why?
|
| Health Services | 1 | 2017 | 113 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2017 | 256 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2015 | 30 | 0.030 |
Why?
|
| Stress, Psychological | 1 | 2017 | 141 | 0.030 |
Why?
|
| Counseling | 1 | 2017 | 189 | 0.030 |
Why?
|
| Educational Status | 1 | 2015 | 200 | 0.030 |
Why?
|
| Insurance Coverage | 1 | 2016 | 106 | 0.030 |
Why?
|
| Internet | 1 | 2017 | 231 | 0.030 |
Why?
|
| Continental Population Groups | 1 | 2017 | 302 | 0.030 |
Why?
|
| Sex Factors | 1 | 2017 | 644 | 0.030 |
Why?
|
| Sigmoidoscopy | 1 | 2014 | 65 | 0.030 |
Why?
|
| Women's Health | 1 | 2014 | 202 | 0.030 |
Why?
|
| Occult Blood | 1 | 2014 | 154 | 0.030 |
Why?
|
| Health Care Reform | 1 | 2012 | 31 | 0.030 |
Why?
|
| Community Health Services | 1 | 2013 | 83 | 0.020 |
Why?
|
| Comparative Effectiveness Research | 1 | 2012 | 66 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 888 | 0.020 |
Why?
|
| Disease Progression | 1 | 2012 | 267 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2014 | 332 | 0.020 |
Why?
|
| Benzo(a)pyrene | 1 | 2011 | 1 | 0.020 |
Why?
|
| Cooking | 1 | 2011 | 17 | 0.020 |
Why?
|
| Hot Temperature | 1 | 2011 | 8 | 0.020 |
Why?
|
| Health Behavior | 1 | 2013 | 360 | 0.020 |
Why?
|
| Formaldehyde | 1 | 2010 | 5 | 0.020 |
Why?
|
| Genotype | 1 | 2011 | 227 | 0.020 |
Why?
|
| Developing Countries | 1 | 2010 | 16 | 0.020 |
Why?
|
| Animals | 1 | 2011 | 262 | 0.020 |
Why?
|
| Quality of Life | 1 | 2012 | 511 | 0.020 |
Why?
|
| Pregnancy Outcome | 1 | 2010 | 158 | 0.020 |
Why?
|
| Pregnancy Complications | 1 | 2010 | 201 | 0.020 |
Why?
|
| Delayed-Action Preparations | 1 | 2007 | 6 | 0.020 |
Why?
|
| Injections | 1 | 2007 | 5 | 0.020 |
Why?
|
| Reproduction | 1 | 2007 | 13 | 0.020 |
Why?
|
| Confounding Factors (Epidemiology) | 1 | 2007 | 86 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2007 | 129 | 0.020 |
Why?
|
| Hazardous Substances | 1 | 2005 | 3 | 0.020 |
Why?
|
| Coloring Agents | 1 | 2005 | 4 | 0.020 |
Why?
|
| Metals | 1 | 2005 | 6 | 0.020 |
Why?
|
| Marital Status | 1 | 2005 | 21 | 0.020 |
Why?
|
| Life Style | 1 | 2007 | 334 | 0.010 |
Why?
|
| Ethics, Research | 1 | 2003 | 1 | 0.010 |
Why?
|
| Breast Self-Examination | 1 | 2003 | 4 | 0.010 |
Why?
|
| Forms and Records Control | 1 | 2003 | 7 | 0.010 |
Why?
|
| Informed Consent | 1 | 2003 | 20 | 0.010 |
Why?
|
| Alcohol Drinking | 1 | 2005 | 373 | 0.010 |
Why?
|